Sector News

In regional shakeup, Novartis’ Alcon fires two Asia execs

June 12, 2015
Life sciences
Two key executives of Novartis subsidiary Alcon with responsibility for Asia were fired this week, AsianScientist reported, after confirming the action by the parent company.
 
Roy Acosta, Asia & Russia region president, and Jim West, Asia & Russia chief financial officer, of global medical company Alcon were fired on June 10, AsianScientist said, noting that Novartis declined to discuss the reasons for the move.
 
In an email response, Novartis confirmed to FiercePharmaAsia that the two executives had left the company.
 
“Novartis can confirm that Roy Acosta, Region President, Asia & Russia, and Jim West, Chief Financial Officer, Asia & Russia, will be leaving the company after 25 years of service, respectively,” a company spokesman said in an email.
 
Eric Van Oppens, who is currently head of the Asia cluster for Novartis Pharma, will replace Acosta as Asia & Russia region president at Alcon, effective July 1, the spokesperson said.
 
Oppens, who is currently head of the Asia Cluster for Novartis Pharma, has been appointed as region president, Asia & Russia at Alcon, effective July 1.
 
Acosta reported directly to Jeff George, head of Alcon and member of the executive committee of Swiss-based Novartis.
 
Alcon, which makes sterile eye care products and operates out of Fort Worth, Texas, is the second-largest division of Novartis; it was bought in 2011 for $51.9 billion.
 
AsianScientist said that Acosta joined Alcon in 1989 and has held various leadership positions within U.S. and International Operations, citing his biography on the company’s website.
 
Alcon faced accusations in 2013 of diverting funds meant for postmarketing surveys to bribe doctors in China.
 
Novartis faced sales sanctions and investigations by regulators last year in Japan over failure to report serious side effects during clinical trials as well as complaints that sales officials had an indirect role in managing data.
 
AsianScientist said a spokesperson for Novartis Media Relations in Basel confirmed that Acosta and West were let go on Wednesday.
 
By EJ Lane
 

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach